Studies that have examined the association between alcohol consumption and gastric cancer (GC) risk have been inconsistent. We conducted an investigation of 29 genetic variants in alcohol metabolism loci (alcohol dehydrogenase, ADH1 gene cluster: ADH1A, ADH1B and ADH1C; ADH7 and aldehyde dehydrogenase, ALDH2), alcohol intake and GC risk. We analyzed data from a nested casecontrol study (364 cases and 1272 controls) within the European Prospective Investigation into Cancer and Nutrition cohort. Single nucleotide polymorphisms (SNPs) were genotyped using a customized array. We observed a statistically significant association between a common 3#-flanking SNP near ADH1A (rs1230025) and GC risk [allelic odds ratio (OR) A v T 5 1.30, 95% confidence interval (CI) 5 1.07-1.59]. Two intronic variants, one in ADH1C (rs283411) and one in ALDH2 (rs16941667), also were associated with GC risk (OR T v C 5 0.59; 95% CI 5 0.38-0.91 and OR T v C 5 1.34; 95% CI 5 1.00-1.79, respectively). Individuals carrying variant alleles at both ADH1 (rs1230025) and ALDH2 (rs16941667) were twice as likely to develop GC (OR A1T 5 2.0; 95% CI 5 1.25-3.20) as those not carrying variant alleles. The association between rs1230025 and GC was modified by alcohol intake (<5 g/ day: OR A 5 0.89, 95% CI 5 0.57-1.39; ‡5 g/day: OR A 5 1.45, 95% CI 5 1.08-1.94, P-value 5 0.05). The association was also modified by ethanol intake from beer. A known functional SNP in ADH1B (rs1229984) was associated with alcohol intake (P-value 5 0.04) but not GC risk. Variants in ADH7 were not associated with alcohol intake or GC risk. In conclusion, genetic variants at ADH1 and ALDH2 loci may influence GC risk, and alcohol intake may further modify the effect of ADH1 rs1230025. Additional population-based studies are needed to confirm our results.
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Introduction
Gastric cancer (GC) is the second leading cause of cancer death worldwide, and infection with Helicobacter pylori is an established risk factor (1, 2) . Alcohol consumption has been investigated as a risk factor in numerous studies but with inconsistent results (3) . Although an association between moderate alcohol consumption and GC risk is unlikely, whether there is an association with higher consumption levels has been difficult to establish. This could be due to several factors, including limited power (sample size), differences in study design and methods of assessing alcohol intake, data analysis strategy (e.g. referent group choice-never drinkers or light drinkers) and population differences in drinking behavior and the capacity to metabolize alcohol and its carcinogenic metabolite acetaldehyde. Evidence from the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort and from a recent meta-analysis suggest that heavy alcohol drinking (!50-60 g/day) increases GC risk (4, 5) .
Seven alcohol dehydrogenase (ADH) genes are located in a cluster on chromosome 4q22-23. ADH1 comprises ADH1A, ADH1B and ADH1C and is in proximity to ADH4, ADH6 and ADH7. ADH1 is important in the conversion of ethanol to its carcinogenic metabolite, acetaldehyde, particularly, during the elimination phase and is expressed mainly in the liver but also in gastric mucosa (6, 7) . ADH7 is expressed in the esophagus and gastric mucosa and is important in pre-absorptive metabolism of ethanol to acetaldehyde in the stomach (7) . The ALDH2 (mitochondrial aldehyde dehydrogenase) gene is located on chromosome 12q24.2, is expressed in the liver (and stomach) and is primarily responsible for the conversion of acetaldehyde to nontoxic acetate (8) (9) (10) . Variants in ADH1 and ALDH2 genes are known to contribute to variation in alcohol metabolism in Asian populations, but specific variants differ in prevalence across populations (9, 11) , and allele effect sizes and influence on alcohol consumption and GC risk are still poorly characterized. To date, three studies have evaluated variation in alcohol metabolism genes and GC risk, a population-based case-control study from the US (12), one from Poland (13) and a small case-control study of multiple aerodigestive tract cancers in Japanese alcoholics (14) . The US-based study identified an association between ADH1C ( Ã 1/ Ã 1) and esophageal adenocarcinoma and cardia GC risk (analyzed together) and non-cardia GC risk. Neither of the other two studies identified a main effect of genetic variants in alcohol genes and GC risk, but the Polish study identified a possible interaction between an ALDH2 variant and alcohol intake (13) .
We conducted a molecular epidemiologic investigation of genetic variation in the ADH1 gene cluster, ADH7 and ALDH2 and risk of gastric adenocarcinoma in the EPIC cohort. We investigated GC risk in relation to the main effects of genetic variants, interactions between variants and interactions with alcohol consumption.
Materials and methods
EPIC cohort study population EPIC is a multicenter prospective cohort of 521 457 participants (368 010 women and 153 447 men) recruited from 23 centres in 10 European countries, including Denmark (Aarhus, Copenhagen), France, Germany (Heidelberg, Potsdam), Greece, Italy (Florence, Turin, Varese, Naples, Ragusa), The Netherlands (Bilthoven, Utrecht), Norway, Spain (Asturias, Granada, Murcia, Navarra, San Sebastian), Sweden (Malmö, Umeå) and the United Kingdom (Oxford, Cambridge) (15) . Most of the participants were enrolled between 1992 and 1998 at ages between 35 and 70 years. Participants were recruited from the general population residing in geographic areas, including towns and provinces. Exceptions were the French cohort (a teacher's organisation health insurance program), cohorts comprised women attending breast cancer screening programs (Utrecht and Florence), parts of the Italian and Spanish cohorts (blood donors) and most of the Oxford cohort (vegetarian volunteers). Written informed consent was obtained from all EPIC participants. The EPIC study and the EurGast nested case-control study of GC (see below) were approved by ethical committees from the International Agency for Research on Cancer and each of the 23 EPIC study centres.
Identification of gastric adenocarcinoma cases in EPIC Follow-up of cohort members for these analyses was performed through 2003-2006, depending upon the study center. Case identification was based on information in population cancer registries except in France, Germany, Greece and Naples (Italy) where a combination of different methods including health insurance records, hospital-based cancer and pathology registries and active follow-up (participant tracking) were used. GC included diagnoses coded as C16 according to the 10th Revision of the International Classification of Disease (ICD-10). Among men and women in the full EPIC cohort, a total of 665 cases of GC were observed (487 adenocarcinomas, 145 non-adenocarcinomas, 7 stump tumors and 26 not specified) of which a total of 444 were incident, primary gastric adenocarcinomas (from here on referred to as gastric cancer or GC). All cases were validated for histological (diffuse, intestinal, mixed or not specified using Lauren's classification) and anatomical subtypes (cardia C16.0, non-cardia C16.1-9, mixed or not specified) by a panel of pathologists who reviewed original pathology reports, tumor slides and paraffin blocks obtained on GC cases from EPIC centers (16) .
Nested case-control study The EurGast nested case-control study of primary incident gastric adenocarcinoma was designed to efficiently study biomarkers and genetic susceptibility in relation to GC risk in the EPIC cohort. Each incident GC case with an available blood sample was matched by age group (±2.5 years), centre, sex and date of blood collection (±45 days) to four control participants randomly selected from the cohort at risk at the time of diagnosis of the index case. After exclusion of cases and controls without baseline alcohol consumption and genotype data, there were 364 GC cases and 1272 controls available for these analyses. Among the 364 cases, there were 179 non-cardias, 106 cardias and 79 mixed/not specified for anatomical subsite and 125 intestinal, 127 diffuse and 112 mixed or unspecified for histological subtype.
Assessment of alcohol consumption
Alcohol consumption (average intake of pure ethanol in grams per day) at baseline was based on food questionnaire assessments, which represent consumption over the 12 months before enrollment in the EPIC cohort. Alcohol intake assessments were based on the number of standard glasses of each type of alcoholic beverage (wine, beer and/or cider, sweet or distilled spirits and fortified wines) consumed per day or per week and on the country-specific average glass volume and alcohol (pure ethanol) content for each type of beverage. Alcohol intake variables were based on grams of pure ethanol per day (from all beverage or from specific beverages) with cutpoints based upon categories used in the full cohort analysis (4) and collapsed to retain statistical power (,5 or !5 g of ethanol per day). In the full cohort, at least 56% of participants who reported non-consumption of alcohol at baseline could be considered former drinkers based upon their lifetime alcohol intake data (assessed in 80% of the cohort by lifestyle questionnaires) (4). Furthermore, in the full cohort analysis, non-consumers at baseline and former drinkers were at elevated risk for GC, suggesting that some former drinkers may have quit due to health problems possibly related to GC risk (4) . Thus, to minimize misclassification of alcohol intake, we reclassified participants who reported non-consumption at baseline using available lifetime intake data. Of the 240 baseline non-consumers in the nested study, 102 were true never drinkers and classified with those consuming ,5 g/day, 79 were former drinkers and classified with those consuming !5 g/day and 59 were missing lifetime data and classified with the group consuming !5 g/day in order to minimize contamination of the low intake group (,5 g/day) with potential former regular drinkers. OR-adjusted for age (5-year categories), sex and country. SD, standard deviation.
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Single nucleotide polymorphism selection and genotyping Genomic DNA was extracted from frozen buffy coats and genotyping performed at the Spanish National Genotyping Center (CEGEN) in Barcelona. This study was part of a candidate gene study of GC susceptibility (EurGast) which genotyped 1536 single nucleotide polymorphisms (SNPs) within 249 gene regions on a customized array using the Illumina BeadStation Platform and GoldenGate technology (Illumina, San Diego, CA) (17) . The SNP selection strategy involved a combination of both common haplotype-tagging SNPs (tagSNPs) and known functional SNPs. Twenty tagSNPs and 3 functional SNPs were selected in the 101-kb region containing ADH1A, ADH1B and ADH1C; 11 tagSNPs were selected in the nearby 55-kb region containing ADH7 and 4 tagSNPs and 1 functional SNP were selected in the 111-kb region containing ALDH2. Five percent of the samples were genotyped in duplicate to assess genotyping error (proportion concordant-99.2%). Of the 39 SNPs selected in alcohol metabolism loci, 10 were eliminated due to QC failure (failure in .20% of samples, deviation from HWE, no amplification or inadequate cluster separation): 7 in ADH1, 1 in ADH7 and 2 in ALDH2.
Statistical analysis
To reduce complexity and correct for multiple testing (multiple SNPs within genes), a permutation test on all 249 genetic loci successfully genotyped in EurGast was performed (18) . The data were permuted on case-control status 10 000 times and the final analysis was adjusted for age (in 5-year categories), sex and country. For each permutation of case-control status, the minimum P-value for each gene was noted and used to form a null distribution to determine the appropriate significance level cutoff for each gene (18) . To account for multiple testing among alcohol metabolism gene SNPs (n 5 29), falsepositive report probabilities (FPRPs) were estimated for SNPs that were found associated with GC risk at standard significance testing cutoffs (a-level 5 0.05) (19) . To estimate FPRP for SNPs with at least one supporting functional study from the literature, the range of prior probabilities was set from 0.1 (high) to 0.01 (medium) and for SNPs with no supporting functional data, the range of prior probabilities was set from 0.01 (medium) to 0.001 (low) (19) .
Unconditional logistic regression modeling was used to estimate the odds ratio (OR) for SNPs, alcohol consumption and GC risk adjusting for age, sex and country. Analyses of SNPs and GC risk used log-additive (per allele), codominant, dominant and recessive models. To retain statistical power, covariates other than age, sex and country were not included in statistical models since the distribution of these factors is not expected to differ by alcohol metabolism genotype (20) . The possibility of population stratification was considered, but since the observed distribution of P-values for the final 1285 SNPs that passed QC was well fitted by a uniform distribution, genomic control was not needed (17) .
Tests for statistical significance of interactions were based on a likelihood ratio test (LRT). Alcohol-SNP and SNP-SNP interactions were explored only for those SNPs with prevalence . 5% in cases and controls and a statistically significant main effect on GC risk (at a-level 5 0.05). A KruskalWallis one-way analysis of variance by ranks test was used to evaluate median alcohol intake in grams per day for each SNP genotype. Tests for trend were performed by ordinal coding of the variable under consideration. All statistical tests were two sided, and all analyses were performed using STATA (version 10.0, College Station, TX) and SNPassoc R library software (21) .
Haplotype analysis
Linkage disequilibrium (LD) between SNPs in each gene region (ADH1, ADH7 and ALDH2) was assessed and haplotype frequencies inferred using the EM algorithm as implemented in the haplo.stats R package. One SNP in ADH1 (rs3133158) was eliminated from haplotype analyses since it was highly correlated with rs1789895 (correlation coefficient 5 0.995). SNPs with .5% missing data were not included in haplotype analyses (rs3811802, rs1229863 and rs1154460). ORs for ADH1, ADH7 or ALDH2 haplotypes with frequency .5% and GC risk were estimated using the most common haplotype as the referent group and were adjusted for age, sex and country. An LD figure for ADH1 and ADH7 based on EPIC-EurGast data was produced in Haploview version 4.2 (22) with graphical enhancements using Adobe Illustrator. 
Alcohol metabolism genes and gastric cancer Results
Distributions of cases and controls according to matching factors (age at recruitment, sex and country) and baseline daily average ethanol intake (grams per day) are provided in Table I . Cases and control were similar with regard to age, sex and country (Table I) . ORs for baseline alcohol intake (grams per day) from all alcoholic beverages or from beer suggest that heavier consumption (!60 or !30 g/day, respectively) is associated with a higher risk of GC (Table I) . OR estimates from the nested study were similar to hazard ratios from the full cohort analysis (4). Ethanol intakes from wine and liquor or spirits were not statistically significantly associated with GC risk in the full cohort or in the nested study (Table I) 
Successfully genotyped SNPs in EurGast accounted for 45% of known common genetic variants at the ADH1 locus, 33% at the ADH7 locus and 80% at the ALDH2 locus. One SNP in ADH1 (rs1693482) that did not genotype properly accounted for 20% of common variation at the ADH1 locus. Functional SNP rs671 in ALDH2 was monomorphic in our study population and functional SNPs rs698 and rs1693482 in ADH1C did not genotype properly due to poor cluster separation (data not shown). An LD map based on EurGast data for the chromosomal region containing all genotyped SNPs in ADH1 and ADH7 is given in Figure 1 . The map shows similar haplotype block structure to what is found for CEU data in HapMap (data not shown). In our data, four haplotype blocks span ADH1A, ADH1B, ADH1C and ADH7, and these were used to evaluate haplotype-associated risk of GC (described below). Since only three SNP markers were genotyped in ALDH2, and all were tags of the same haplotype block, no LD map is given for this locus.
Main effect of variants in alcohol metabolism genes and SNP Ã SNP interaction Information and allelic ORs for each SNP marker are found in Table II . Of all markers analyzed, three were associated with a statistically significant risk of GC-rs1230025 (an intergenic SNP flanking the 3# untranslated region of ADH1A) was associated with a 30% higher risk of GC, rs283411 (an intronic SNP in ADH1C) was associated with a 41% lower risk of GC and rs16941667 (an intronic SNP in ALDH2) tended to be associated with a 34% higher risk of GC (Table II) . FPRPs were estimated for the three markers in association with GC risk from Table I (FPRP data not We evaluated the combined effect of the two common SNPs showing associations with GC (ADH1 rs1230025 and ALDH2 rs16941667) (Table III) . Individuals with variant alleles at both SNP sites had a doubling of GC risk in comparison with individuals with non-variant alleles at both sites (Table III ). An LRT for rs1230025 and rs16941667 yielded a P-value of 0.27; however, the variant A allele in rs1230025 was not significantly associated with GC risk in those with the common C allele in rs16941667; likewise, the variant T allele in rs16941667 was not associated with GC risk in those with the common T allele in rs1230025 (Table III) . The SNP in ADH1C (rs283411) was too rare (,5%) in our study population to evaluate interactions or combined effects with the other two SNPs.
We ran logistic regression models of GC risk, including all three SNPs showing an association with GC (rs1230025, rs283411 and rs16941667), adjusting for ethanol intake (from all alcoholic beverages or from beer), age, sex and country. In these models, the OR for each SNP was statistically significant and virtually identical in magnitude to the individual ORs for these SNPs found in Table II (data not shown).
Cardia/non-cardia and diffuse/intestinal
We evaluated the adjusted main effect of each SNP on GC risk by anatomical location and histological subtype. The OR for rs1230025 was the same in magnitude by anatomical subsite and by histology (data not in tables). The OR for ADH1C SNP rs283411 was similar by anatomical subsite but was statistically significant in GC of the diffuse subtype (allelic OR 5 0.30, 0.12-0.75). Intergenic SNP rs1229982 near ADH1B was not associated with GC risk overall (Table II) Alcohol metabolism SNPs and alcohol drinking propensity in controls A known functional variant in ADH1B (rs1229984) was statistically significantly associated with alcohol intake in controls: in G/G carriers (n 5 1133, median ethanol from all alcoholic beverages 5 7.3 g/ day), in G/A carriers (n 5 132, median 5 5.3 g/day) and in A/A carriers (n 5 6, median 5 1.4 g/day)-Kruskal-Wallis one-way analysis of variance by ranks P-value 5 0.036. The equivalent median grams per day from beer were 0.7, 0.2, and 0.0, respectively (P-value 5 0.0002). No other SNPs were statistically significantly associated with alcohol intake in controls (data not shown).
Modification of genetic effects on GC risk by alcohol intake
We next investigated modification of the association between ADH1 rs1230025 and ALDH2 rs16941667 variants and GC risk by alcohol intake. We also show the effect of the ADH1B rs1229984 functional variant on GC risk stratified by alcohol intake (Table IV) . ADH1A rs1230025 showed a statistically significant interaction with total alcohol intake (P-value 5 0.050, dominant model) and with beer intake (P-value 5 0.004, codominant model, although the CI was wide) in relation to GC risk (Table IV) . There was no evidence for interactions between alcohol intake and ADH1B rs1229984 or ALDH2 rs16941667 (Table IV) . ORs for GC risk and the combined effect of ADH1 rs1230025 and ALDH2 rs16941667 tended to be elevated among heavier alcohol drinkers, but LRTs were not statistically significant (Table IV) .
Haplotype analysis of alcohol metabolism genes
We performed haplotype analyses of two LD blocks in ADH1, two blocks in ADH7 and one block in ALDH2 (Table V) . With the exception of one haplotype in block 1 of the ADH1 gene cluster (AGAT, containing the A allele of rs1230025) showing a tendency for higher GC risk, the remaining haplotypes at all three loci were not statistically significantly associated with GC risk (Table V) .
Discussion
We examined associations between genetic variants in alcohol metabolism loci (ADH1A, ADH1B, ADH1C, ADH7 and ALDH2), alcohol consumption and GC risk in the EPIC cohort and found associations with an SNP near the ADH1A 3# untranslated regions (rs1230025), an intronic SNP in ADH1C (rs283411) and an intronic SNP in ALDH2 (rs16941667). After accounting for multiple testing and one previous functional study, rs1230025 (near ADH1A) was considered a potentially noteworthy marker of GC risk. We found that the effect on GC risk of alleles at ADH1A rs1230025 and ALDH2 rs16941667 is most apparent when both variant alleles are present. We also evaluated the effect of statistically significant SNPs on GC risk by alcohol intake and identified a potential 'gene-environment interaction' (significant cross-product term) between rs1230025 and moderate to heavy alcohol or beer drinking. A known functional SNP in ADH1B (rs1229984, G/A) was inversely associated with alcohol intake in control participants (but not with GC risk), providing support for the hypothesis that Table III . ORs for the combined effect of ADH1 and ALDH2 genotypes and GC risk, EPIC-EurGast Four participants were missing data on ADH1 (rs1230025) and/or ALDH2 (rs16941667). a OR-adjusted for age, sex and country. Alcohol metabolism genes and gastric cancer the minor allele is associated with alcohol avoidance (11, 23) . With the exception of one haplotype in the ADH1 gene cluster (AGAT, containing the A allele of rs1230025), no other haplotypes were associated with GC risk in this study. A logistic regression model for GC risk including all three SNPs and adjusting for alcohol intake, age, sex and country suggested that at least some of the effect of these variants on GC risk may involve the metabolite acetaldehyde, independent of alcohol intake levels. A previous case-control study from the US reported an association between ADH1C variant rs698 and GC risk (based on 114 esophageal cancer and cardia GC cases combined and 60 non-cardia GC cases), but the effect was not modified by alcohol intake (12) . SNP rs698 did not genotype properly in our study and, therefore, was excluded from analysis. Another case-control study conducted in Poland (based on 305 GC cases and 428 controls) reported no main effects for seven SNPs in ADH1B, ADH1C and ALDH2 but reported a potential interaction between ALDH2 rs886205 and alcohol intake in relation to GC risk (13) . Only three SNPs from the Polish study (rs17033 and rs1229984 in ADH1B and rs886205 in ALDH2) were also analyzed in our study. We did not observe evidence for an interaction between ALDH2 rs886205 and alcohol intake in EPIC (LRT P-value 5 0.89). In a small case-control study of Japanese alcoholics, a positive association between ALDH2 Ã 2 (rs671, monomorphic in our study population) and GC in patients with concurrent oralpharyngeal or esophageal cancers was reported (14) . Genetic variants in ADH1B and ALDH2 are known to increase the risk of esophageal cancer, and risk is further modified by alcohol consumption (24) . Furthermore, acetaldehyde is a known esophageal carcinogen (3) and a hypothesized gastric carcinogen (25, 26) .
Gastric mucosa expresses ADH and it is thought that a significant amount of consumed alcohol is metabolized in the stomach (27) . Thus, there may be substantial production of acetaldehyde in the gastric tissues of heavy drinkers, and this may be further compounded when carrying variant alleles in ADH1 and ALDH2. The function of ADH1 rs1230025 is not established; however, a recent analysis in the Australian Alcohol Challenge Twin Study reported a statistically significant association with early stage (pre-absorptive) in vivo alcohol metabolism (i.e. the variant allele was associated with more rapid metabolism of ethanol, and presumably, higher acetaldehyde levels) (6) . The possible function of ALDH2 rs16941667 is as yet unknown (it was not associated with alcohol use, reactions or dependence in the Australian twin study) (28) . Our results showing elevated risk in carriers of both alleles might suggest that the rs16941667 variant in ALDH2 results in decreased metabolism of acetaldehyde. In our control population, rs1230025 and rs16941667 were not associated with propensity to drink alcohol (based on grams per day).
Our results suggest that heavy alcohol or beer consumption modifies the effect of the ADH1 rs1230025 variant. Beer is known to contain low levels of nitrosamines (N-nitrosodemethylamine or NDMA), a suspected gastric carcinogen. Furthermore, heavy alcohol consumption has been shown to induce CYP2E1 in both animals and humans and induced CYP2E1 can generate reactive oxygen species and activate procarcinogens, such as nitrosamines found in beer (and in tobacco smoke and preserved foods) (9) . We hypothesize that our results showing interactions between rs1230025 near ADH1 and heavy alcohol (and beer) consumption might be explained by elevated acetaldehyde levels due to heavy drinking in the context of variant alleles in rs1230025 (and rs16941667), plus possible low levels of nitrosamines from beer. Chronic exposure to these chemicals in the gastric mucosa may lead to exacerbation of existing mucosal damage, inflammation and immune reaction (due to H. pylori infection and chronic atrophic gastritis) (29, 30) and subsequent increases in DNA damage, cell turnover rate and progression of gastric lesions.
Our study has some weaknesses including limited power to detect interactions and to evaluate sex-specific results. Alcohol intake data in these analyses generally refer to the 12-month period prior to cohort enrollment (and may not reflect long-term drinking patterns). Some selected SNPs in our study did not genotype successfully, and as a result, between 33 and 80% of known common genetic variation in ADH1, ADH7 and ALDH2 was accounted for. We acknowledge the possibility that other SNPs and other alcohol metabolism genes that we did not evaluate in our study could be associated with GC risk. We did not evaluate rare (,5%) variants, and additional genes not examined in our study may also contribute to overall variation in alcohol metabolism (e.g. CYP2E1). The study of genetic variation in alcohol/ acetaldehyde metabolism, alcohol intake and cancer risk is complicated by the complex interrelations among multiple functional variants that may influence both the propensity to drink alcohol and the metabolism of alcohol and acetaldehyde. How these may influence various phenotypes, such as alcohol reactions (flushing and nausea), intoxication, dependency and risk of alcohol-related cancer further adds to the complexity. The prospective nature of our study meant that alcohol consumption information was collected on average 8-9 years before GC diagnosis, eliminating some of the potential biases associated with retrospective collection of exposure information.
In conclusion, we found associations between GC risk and three loci marked by ADH1 rs1230025 and rs283411 and ALDH2 rs16941667. Associations between GC and rs1230025 or rs16941667 SNPs were observed predominantly in individuals who had variant alleles at both loci, suggesting that the concerted action of ADH1 and ALDH2 variants could result in higher GC risk. We also observed higher genetic risk in participants with higher alcohol intake as measured at baseline in EPIC (8-9 years before GC diagnosis). Finally, the function of these genetic variants needs to be evaluated in European populations, and our results replicated before definitive conclusions or public health recommendations can be made. ADH1 block 1 (rs1230025, rs13123099, rs17033, rs13133908), ADH1 block 2 (rs1229980, rs1789895, rs1614972, rs283410, rs283411, rs4699741, rs17586246), ADH7 block 3 (rs1442490, rs994772, rs7663410, rs284792, rs729147), ADH7 block 4 (rs971074, rs1154473, rs1154476) and ALDH2 (rs886205, rs968529, rs16941667). a OR-adjusted for age, sex and country.
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